VRDN - Viridian Therapeutics, Inc.\DE
IEX Last Trade
19.53
0.250 1.280%
Share volume: 5,950
Last Updated: Thu 26 Dec 2024 04:30:27 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
4.47%
PREVIOUS CLOSE
CHG
CHG%
$19.28
0.25
1.30%
Fundamental analysis
24%
Profitability
25%
Dept financing
3%
Liquidity
75%
Performance
16%
Performance
5 Days
1.47%
1 Month
-8.18%
3 Months
-9.77%
6 Months
51.33%
1 Year
-14.02%
2 Year
-34.72%
Key data
Stock price
$19.53
DAY RANGE
$19.01 - $19.47
52 WEEK RANGE
$11.99 - $27.20
52 WEEK CHANGE
-$14.18
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO: Jonathan Violin
Region: US
Website: viridiantherapeutics.com
Employees: 50
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: viridiantherapeutics.com
Employees: 50
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Viridian Therapeutics, Inc. develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED) The company was founded in 2006 and is headquartered in Waltham, Massachusetts.
Recent news